Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH
Nick van Es/Author of the Article
Feb 24, 2026, 13:29

Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH

Journal of Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Nick van Es et al, adding:

”The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE Cancer trial

Novel win ratio analysis comparing edoxaban versus dalteparin in cancer-associated VTE reveals no significant difference between treatments when evaluating hierarchically prioritized outcomes including mortality, recurrent events, and bleeding complications.”

Title: The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial

Authors: Nick van Es, Luuk J.J. Scheres, Kristen M. Sanfilippo, Harry Büller, Marc Carrier, Marcello Di Nisio, Michael Grosso, Renato D. Lopes, William F. McIntyre, Bjorn Redfors, Annelise Segers, Peter Verhamme, Jeffrey I. Weitz, Patrick M. Bossuyt, Deborah M. Siega

Read the Full Article on Journal of Thrombosis and Haemostasis.

Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE - JTH

Stay updated with Hemostasis Today.

Annelise Segers Björn Redfors cancer dalteparin Deborah M. Siega edoxaban Harry Büller Health Hematology Hemostasis Hemostasis News Hemostasis Today Jeffrey I. Weitz Journal of Thrombosis and Haemostasis JTH Kristen M. Sanfilippo Luuk J.J. Scheres Marc Carrier Marcello Di Nisio Medicine Michael Grosso Nick van Es Patrick M. Bossuyt Peter Verhamme Renato D. Lopes thrombosis VTE William F. McIntyre
NewsFeed